ArticleFrontiers in immunology2026
A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLC.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) provide durable benefit for a subset of patients with advanced non-small cell lung cancer (NSCLC), however predictive biomarkers remain limited. Peripheral blood offers accessible immune and inflammatory signals that may reflect the onset of systemic mechanisms of resistance. This study aimed to identify circulating immune features associated with clinical outcome and to develop a clinically applicable blood-based score for risk stratification in patients receiving ICIs. Methods: Two independent real-world cohorts of advanced NSCLC patients treated with anti-PD-1 therapy were analyzed. Plasma cytokines and chemokines, soluble immune checkpoint molecules and blood cell counts were measured before and during ICI-therapy. Baseline biomarkers associated with progression-free survival (PFS) and overall survival (OS) were incorporated into an Immune-Suppressive Blood Index Score (ISBIS). The ISBIS discriminative performance was first determined in the discovery cohort (n=57) and then validated in an independent cohort (n=56), and nomogram integrating ISBIS with clinical variables was generated. Results: ISBIS score predicts poor outcome to be associated with an immunosuppressive blood profile composed of baseline IL-6, IL-8, CCL2, CXCL10, neutrophils, PLR, IFN-γ and lymphocytes. On-treatment increase in CXCL10, neutrophils, and NLR, as well as decreases in lymphocytes and soluble PD-L2, were associated with early disease progression. ISBIS stratified patients into three risk groups with significantly different survival in both cohorts and remained independently associated to OS. A nomogram combining ISBIS with ECOG-PS (Eastern Cooperative Oncology Group - Performance Status), disease burden, sex, and NLR (neutrophil-to-lymphocyte ratio) demonstrated strong discrimination and validated accuracy. Conclusions: A systemic immune-suppressive profile identifies patients with poor outcomes to ICIs. ISBIS integrates critical immune and inflammatory signals into a clinically applicable tool, supporting personalized immunotherapy strategies in advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.